Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS Genet
Hauptverfasser: Hamieh, Lana, Choueiri, Toni K., Ogórek, Barbara, Khabibullin, Damir, Rosebrock, Daniel, Livitz, Dimitri, Fay, Andre, Pignon, Jean-Christophe, McDermott, David F., Agarwal, Neeraj, Gao, Wenhua, Signoretti, Sabina, Kwiatkowski, David J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2018
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181431/
https://ncbi.nlm.nih.gov/pubmed/30256787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pgen.1007679
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge